GAINESVILLE, Fla., Oct. 06, 2015 (GLOBE NEWSWIRE) -- AmnioLife Corporation, a human cells, tissues, and cellular and tissue-based products developer, today announced that its CEO and Lead Scientist will participate in the first annual Interventional Orthopedic Foundation Conference (http://interventionalorthopedics.org) on October 23rd and 24th at the Omni Resort in Broomfield, CO. It is scheduled to feature talks from leading physicians on the future of orthopedic therapies with a specific focus on regenerative medicine.
AmnioLife will present a data summary to highlight key molecular features of its injectable purified amniotic fluid, Xceed™, and its purified amniotic membrane, ProLifixTM, including protein stability, cytokine profiling, and other analyses. AmnioLife’s Lead Scientist, Sam Fagg, stated, “We look forward to attending the IOF meeting and presenting data that demonstrate how our minimally manipulated products retain many growth factors and cytokines. Additionally, taking part in the meeting will allow us to stay on the cutting edge of developing therapeutic products, and to discuss potential products and treatment methods with leading physicians in orthopedic regenerative medicine.”
This conference brings together pioneers in this new and exciting field to share their latest research. Conference presentations will address current clinical and research topics and allow physicians to determine the best practices in interventional orthopedics as well as the standardization of orthobiologics.
About AmnioLife
AmnioLife is a research and development organization focused on placental-derived technologies and is building a comprehensive manufacturing program at its Gainesville, FL facility. The Company aims to commercialize a suite of minimally manipulated tissue products, global sales channel partners, and develop a strong IP-position for advanced biologic products. For more information, visit our website at http://www.amniolife.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws that are forward-looking, and based on the current expectations and beliefs of AmnioLife’s management team. The forward-looking statements contained in this press release are subject to a number of factors and uncertainties that could cause actual results to differ materially. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and marketplace requirements; delays or obstacles in launching and/or successfully completing some of the clinical study initiatives; products may not be approved by regulatory agencies or regulations may change affecting desired results; inability to retain or attract key employees whose knowledge is essential to the development of required technologies and products; unforeseen scientific difficulties may develop with our process; our patent(s) may not be sufficient; inability to timely develop and introduce new technologies; inability to obtain additional funding; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of AmnioLife to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, AmnioLife disclaims any obligation to publicly release any revisions to these forward-looking statements.